Rapport Therapeutics develops small molecule drugs for neurological and psychiatric disorders, led by a candidate for focal onset seizures. RAPP reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 21 | Jones Trading | Maintained | Buy | |
| Oct 21 | Wells Fargo | Maintained | Buy | |
| Oct 21 | Guggenheim | Target raised | Buy | |
| Oct 15 | UBS | Initiated | Buy | |
| Oct 15 | Wolfe Research | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in RAPP in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RAPP is in one of them and how their past RAPP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RAPP in an article yet. Here's the latest on the wider market.
About Rapport Therapeutics
Rapport Therapeutics is a biotechnology company based in Boston, Massachusetts, that develops small molecule drugs for neurological and psychiatric disorders. Its lead candidate, RAP-219, is being studied for focal onset seizures, a form of epilepsy, and is also being evaluated for generalized seizures and bipolar mania. The company is also developing an injectable version of that candidate and earlier-stage programs aimed at chronic pain, migraine, and hearing and balance disorders. Its intended market is patients with these conditions and the physicians who treat them.
- Headquarters
- Boston, MA